413 related articles for article (PubMed ID: 32273348)
1. Lifting the innate immune barriers to antitumor immunity.
Rothlin CV; Ghosh S
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273348
[TBL] [Abstract][Full Text] [Related]
2. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
3. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells and anti-tumor immunity.
Nicholson SE; Keating N; Belz GT
Mol Immunol; 2019 Jun; 110():40-47. PubMed ID: 29233542
[TBL] [Abstract][Full Text] [Related]
5. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
6. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
8. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice.
Wen L; Xin B; Wu P; Lin CH; Peng C; Wang G; Lee J; Lu LF; Feng GS
Hepatology; 2019 Jun; 69(6):2518-2532. PubMed ID: 30693544
[TBL] [Abstract][Full Text] [Related]
9. Expression of checkpoint molecules on myeloid-derived suppressor cells.
Ballbach M; Dannert A; Singh A; Siegmund DM; Handgretinger R; Piali L; Rieber N; Hartl D
Immunol Lett; 2017 Dec; 192():1-6. PubMed ID: 28987474
[TBL] [Abstract][Full Text] [Related]
10. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
11. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells.
Zwirner NW; Croci DO; Domaica CI; Rabinovich GA
Curr Pharm Des; 2010 Jan; 16(3):255-67. PubMed ID: 20109135
[TBL] [Abstract][Full Text] [Related]
12. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
13. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
15. Targeting phagocytosis to enhance antitumor immunity.
Huntoon K; Lee D; Dong S; Antony A; Kim BYS; Jiang W
Trends Cancer; 2023 Aug; 9(8):650-665. PubMed ID: 37150626
[TBL] [Abstract][Full Text] [Related]
16. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
Front Immunol; 2019; 10():910. PubMed ID: 31105707
[TBL] [Abstract][Full Text] [Related]
17. Regulation of innate and adaptive antitumor immunity by IAP antagonists.
Dougan SK; Dougan M
Immunotherapy; 2018 Jul; 10(9):787-796. PubMed ID: 29807457
[TBL] [Abstract][Full Text] [Related]
18. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
20. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
